<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Enterocutaneous and enteroatmospheric fistulas</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Enterocutaneous and enteroatmospheric fistulas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Enterocutaneous and enteroatmospheric fistulas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sharon L Stein, MD, FACS, FASCRS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eileen M Bulger, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David I Soybel, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 03, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H18524881"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A fistula is an abnormal connection between two epithelialized hollow spaces or organs. Strictly speaking, an enterocutaneous fistula connects the small bowel to the skin. A more liberal interpretation of the term, however, also includes enteric fistulas originating from the colon, stomach, and esophagus. (See <a class="local">'Classification'</a> below.)</p><p>The clinical features, diagnosis, and management of enterocutaneous fistulas are reviewed here. Enteroatmospheric fistulas, which are a subset of enterocutaneous fistulas that occur in the setting of an open abdomen, are also discussed here. </p><p>Fistulas that occur in other areas of the body are discussed in other topics, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Colovesical fistulas (see  <a class="medical medical_review" href="/d/html/104293.html" rel="external">"Colovesical fistulas"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urogenital tract fistulas in women (see  <a class="medical medical_review" href="/d/html/8071.html" rel="external">"Urogenital tract fistulas in females"</a> and  <a class="medical medical_review" href="/d/html/1385.html" rel="external">"Rectovaginal and anovaginal fistulas"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anorectal fistulas (see  <a class="medical medical_review" href="/d/html/83103.html" rel="external">"Anorectal fistula: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/13508.html" rel="external">"Operative management of anorectal fistulas"</a> and  <a class="medical medical_review" href="/d/html/4082.html" rel="external">"Perianal Crohn disease"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic fistulas </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Duodenal fistulas (see  <a class="medical medical_review" href="/d/html/15168.html" rel="external">"Postgastrectomy duodenal leak"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tracheoesophageal fistulas (see  <a class="medical medical_review" href="/d/html/115157.html" rel="external">"Tracheo- and broncho-esophageal fistulas in adults"</a>) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bronchopleural fistulas (see  <a class="medical medical_review" href="/d/html/115897.html" rel="external">"Bronchopleural fistula in adults"</a>)</p><p></p><p class="headingAnchor" id="H21348973"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>Enterocutaneous fistulas can be classified according to source, output volume, and etiology. </p><p></p><p class="headingAnchor" id="H396952927"><span class="h2">By source</span><span class="headingEndMark"> — </span>The most common method of defining a fistula is by its organ of origin (eg, gastro-, duodeno-, entero-, jejuno-, ileo-, colo-, recto-) followed by the point of its termination (eg, -cutaneous, -atmospheric). However, at initial presentation, the specific segment of bowel involved (ie, the enteric origin of the fistula) is often unknown, and a broader designation (eg, enterocutaneous rather than jejunocutaneous) is used until the anatomy of the fistula can be delineated. (See <a class="local">'Diagnosis'</a> below.)</p><p>Fistulas originating from different organ systems will have very different outputs. Electrolyte and nutritional losses can vary greatly between organs of origin. As an example, gastric output has a higher acidity. This information may prove essential in the management of enterocutaneous fistulas. (See <a class="local">'Fluid therapy'</a> below.)</p><p class="headingAnchor" id="H1382051795"><span class="h2">By output volume</span><span class="headingEndMark"> — </span>The physiologic consequences of enterocutaneous fistulas may depend on the quantity of fluid put out by the fistula, which may differ by the location (proximal versus distal) and the length or diameter of the fistula. An alternative classification defines fistulas by the quantity of their output:</p><p class="bulletIndent1"><span class="glyph">●</span>A low-output fistula drains less than 200 mL/day.</p><p class="bulletIndent1"><span class="glyph">●</span>A moderate-output fistula drains between 200 and 500 mL/day.</p><p class="bulletIndent1"><span class="glyph">●</span>A high-output fistula drains more than 500 mL/day.</p><p></p><p>In general, high-output fistulas are less likely to heal spontaneously, and patients with high-output fistulas are at a higher risk for metabolic disturbances, fluid loss, and malnutrition. For such patients, controlling external fistula output is as important as replacing fluid and electrolyte loss during the chronic phase of management. (See <a class="local">'Fistula output reduction'</a> below.)</p><p class="headingAnchor" id="H1999310177"><span class="h2">By etiology</span><span class="headingEndMark"> — </span>Enterocutaneous fistulas can also be classified according to their etiologies (eg, iatrogenic, spontaneous), which are further discussed below. (See <a class="local">'Etiology and risk factors'</a> below.)</p><p class="headingAnchor" id="H2932997131"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Although a few studies have reported postoperative prevalences of enterocutaneous fistulas in patients undergoing surgery for trauma (1.5 percent [<a href="#rid1">1</a>]), general surgery (3.6 percent [<a href="#rid2">2</a>]), and Crohn disease (15 to 35 percent [<a href="#rid3">3,4</a>]), the prevalence of enterocutaneous fistulas in the general population (including both iatrogenic and spontaneous cases) is not well known. The National Inpatient Sample (NIS) noted 317,000 admissions between 2004 and 2014 with a diagnosis of enteric fistula, costing the United States hospital systems more than 500 million dollars annually [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H21348418"><span class="h1">ETIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Various etiologies can lead to fistula formation  (<a class="graphic graphic_table graphicRef76953" href="/d/graphic/76953.html" rel="external">table 1</a>). Most enterocutaneous fistulas are iatrogenic/postoperative (75 to 85 percent); a minority (15 to 25 percent) develop spontaneously [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H21348455"><span class="h2">Iatrogenic fistulas</span><span class="headingEndMark"> — </span>Iatrogenic causes of enterocutaneous fistula include trauma and surgery (ie, postoperative fistulas). Postoperative fistulas develop from either a bowel anastomotic leak (50 percent) or a missed enterotomy (45 percent), with a small percentage from erosion of foreign material (eg, mesh for hernia repair, vascular graft) into adjacent bowel [<a href="#rid7">7</a>]. Preoperative factors that increase the likelihood of the development of a postoperative fistula include Crohn disease, malnutrition, immunosuppression, traumatic injury, infection, smoking, and emergency procedures [<a href="#rid8">8,9</a>]. </p><p class="headingAnchor" id="H2401710484"><span class="h3">Enteroatmospheric fistulas</span><span class="headingEndMark"> — </span>Enteroatmospheric or exposed fistulas occur in the midst of an open abdomen with no overlying soft tissue  (<a class="graphic graphic_picture graphicRef58058" href="/d/graphic/58058.html" rel="external">picture 1</a>). The open abdomen is usually the result of a damage control laparotomy, which leaves the abdomen open after trauma or emergency surgery to prevent intra-abdominal hypertension/abdominal compartment syndrome [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/d/html/2889.html" rel="external">"Abdominal compartment syndrome in adults"</a>.)</p><p>A review of 517 patients from the American Association for Surgery in Trauma (AAST) registry with open abdomen found that 111 patients (21 percent) developed an enterocutaneous fistula, an enteroatmospheric fistula, or intra-abdominal sepsis. Independent risk factors included large bowel resection, large-volume resuscitation, and an increasing number of abdominal re-explorations [<a href="#rid12">12</a>]. The risks of open abdomen are further discussed separately. (See  <a class="medical medical_review" href="/d/html/15145.html" rel="external">"Management of the open abdomen in adults", section on 'Complications of open abdomen'</a>.)</p><p class="headingAnchor" id="H2662565952"><span class="h2">Spontaneous fistulas</span><span class="headingEndMark"> — </span>The mnemonic "FRIEND" describes common etiologies for spontaneous enterocutaneous fistulas, which include <strong>f</strong>oreign body, <strong>r</strong>adiation, <strong>i</strong>nflammation (eg, Crohn disease) or <strong>i</strong>nfection (eg, tuberculosis, actinomycosis), <strong>e</strong>pithelialization, <strong>n</strong>eoplasia, and <strong>d</strong>istal obstruction [<a href="#rid10">10</a>]. These etiologies also describe conditions in which fistulas are less likely to heal spontaneously. Diverticular disease and appendicitis are also reported as uncommon etiologies of fistulas. </p><p>Crohn disease is the most common etiology for spontaneous fistulas; the prevalence varies by patient populations [<a href="#rid10">10,13</a>]. Between 27 and 35 percent of patients undergoing surgery for Crohn disease had a fistula [<a href="#rid3">3,4</a>], while 15.4 percent of patients with complicated Crohn disease, but who had not had surgery, had a fistula [<a href="#rid14">14</a>]. Crohn-related fistulas are typically treated initially with immunosuppressive drugs (thiopurines), biologic agents (TNF inhibitors), and antibiotics (<a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) to reduce inflammation and diarrhea. Medical treatment of Crohn-related fistulas is discussed in another topic. (See  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults", section on 'Features of transmural inflammation'</a>.)</p><p class="headingAnchor" id="H21348503"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The most common presentation of an enterocutaneous fistula is in a postoperative patient who fails to recover normally from abdominal surgery. The patient often presents first with abdominal symptoms, including increased pain, nausea and vomiting, obstipation, and fullness or induration of the abdominal wall. These may be accompanied by fever and leukocytosis. A wound infection is then typically recognized 7 to 10 days postoperatively, and following incisional drainage, enteric contents appear in the surgical wound [<a href="#rid7">7</a>]. An enteric fistula can be distinguished from a wound infection by the presence of bile in the wound. As opposed to infection or seroma, bilious output will stain gauze and dressings an orange/brown or green color. Frank stool can also be noted in the wound of a colonic fistula. </p><p>Enterocutaneous fistulas are characterized by leakage of enteric or bowel contents through the abdominal wall. The leakage is also referred to as effluent. Depending upon the location and origin of the fistula, it can be through a prior abdominal wound, incision, or an area of "virgin" abdomen. Leakage of effluent can cause irritation of the skin, loss of fluids and electrolytes, malnutrition, and infection. In addition, as a fistula is forming, the patient may become acutely ill secondary to leakage of effluent into the abdominal cavity.</p><p class="headingAnchor" id="H21348536"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of an enterocutaneous fistula is clinical. It should be suspected in a postoperative patient who fails to recovery normally from abdominal surgery and has bilious wound drainage. The diagnosis of enterocutaneous fistula can be confirmed by the appearance of enteric contents draining from the abdominal wall. If in doubt, bilirubin levels can be sent from the wound drainage to determine if contents are enteric. </p><p>By definition, an enteroatmospheric fistula can only be diagnosed in a patient with an open abdomen. Similar to enterocutaneous fistulas, the diagnosis can be confirmed by the presence of enteric contents draining from an opening in a segment of bowel within the open abdominal wound.</p><p>However, the organ of origin of an enterocutaneous or enteroatmospheric fistula is often not defined until imaging studies can be performed. (See <a class="local">'Diagnostic evaluation'</a> below.)</p><p class="headingAnchor" id="H2314588946"><span class="h2">Diagnostic evaluation</span><span class="headingEndMark"> — </span>For stable patients with an enterocutaneous or enteroatmospheric fistula, we perform abdominal computed tomography (CT) with and without oral and intravenous contrast at least 7 to 10 days after fluid and electrolyte resuscitation, infection control, and appropriate wound care [<a href="#rid15">15</a>]. CT can not only help delineate the anatomy of the fistula but also demonstrate associated intra-abdominal abscesses, fluid collections, or areas of distal intestinal obstruction. These are all risk factors for fistula formation and persistence. (See <a class="local">'Etiology and risk factors'</a> above.)</p><p>If abdominal CT does not elucidate fistula anatomy, a gastrointestinal contrast study is performed. Either a small bowel follow-through or contrast enema is selected depending upon the suspected level of the fistula (upper versus lower gastrointestinal tract). It should be noted that only the portion of the bowel in continuity will be evaluated by traditional contrast studies. As an example, a mass or stricture (inflammatory or malignant) distal to the fistula may not be well demonstrated, because most of the contrast is drained via the fistula. </p><p>Alternatively, for enterocutaneous fistulas that have a well-defined cutaneous opening, a fistulogram can be performed by injecting a water-soluble contrast agent into the opening to define the fistula tract. Although a fistulogram can document intestinal continuity and evaluate for distal obstruction [<a href="#rid7">7,16,17</a>], it rarely identifies the specific origin of the tract [<a href="#rid10">10</a>]. </p><p>Small fistulas or low-output fistulas may not be apparent on imaging. Another simple method to determine whether or not an enterocutaneous or enteroatmospheric fistula is indeed present is by the administration of dye (eg, <a class="drug drug_general" data-topicid="9088" href="/d/drug information/9088.html" rel="external">indigo carmine</a>, <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a>, charcoal), which can be ingested or added to enteric feeding or instilled as a solution into the gastrointestinal tract during endoscopy. The presence of dye in the effluent confirms the diagnosis of an enteric fistula.</p><p class="headingAnchor" id="H21348543"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Drainage from an abdominal incision following gastrointestinal surgery may represent a surgical site infection rather than an enterocutaneous fistula. The character of the drainage, and whether drainage persists once the wound has been opened, usually makes the distinction as the presence of feces or bile is definitive evidence of an enterocutaneous or enteroatmospheric fistula. (See  <a class="medical medical_review" href="/d/html/15100.html" rel="external">"Wound infection following repair of abdominal wall hernia"</a>.)</p><p class="headingAnchor" id="H239525519"><span class="h1">TREATMENT OVERVIEW</span><span class="headingEndMark"> — </span>The treatment of enterocutaneous and enteroatmospheric fistulas requires a systematic approach and is carried out in phases  (<a class="graphic graphic_table graphicRef57027" href="/d/graphic/57027.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef118853" href="/d/graphic/118853.html" rel="external">algorithm 1</a>). </p><p>Initial acute management focuses on control and treatment of sepsis, which requires surgery in some patients but can be accomplished nonoperatively in others (eg, with antibiotics and catheter drainage). (See <a class="local">'Acute management'</a> below.) </p><p>Once sepsis is controlled, the treatment enters a chronic phase, which focuses on wound management, fluid/electrolyte replacement, and nutritional optimization. It may be appropriate to transfer patients to a specialized center for this phase of the care and beyond [<a href="#rid18">18</a>], where improved outcomes, including a lower mortality rate, have been realized [<a href="#rid10">10,19,20</a>]. This phase of fistula management optimizes the condition for spontaneous healing while simultaneously preparing the patient for possible definitive management. Most contemporary studies report that approximately one-third of enterocutaneous fistulas will close spontaneously within five to six weeks with conservative measures [<a href="#rid13">13,21-27</a>]. (See <a class="local">'Chronic management'</a> below.)</p><p>For fistulas that fail to close spontaneously, the final stage of management is definitive fistula repair, which may be endoscopic or surgical. As long as fistula output is gradually decreasing and the wound (or tract) shows signs of healing, surgery should be delayed. Surgical fistula repair should not be attempted for at least three to six months from the inciting event to allow time for spontaneous healing and patient conditioning. Specialized centers often delay definitive operations for 6 to 12 months [<a href="#rid6">6</a>]. Prerequisites to definitive fistula repair include eradication of infection, optimization of nutrition, and clinical evidence of softening scars and abdominal wall on physical exam. (See <a class="local">'Nonoperative fistula closure'</a> below and <a class="local">'Operative fistula closure'</a> below.)</p><p class="headingAnchor" id="H2349590282"><span class="h1">ACUTE MANAGEMENT</span><span class="headingEndMark"> — </span>Initial treatment of enterocutaneous and enteroatmospheric fistulas focuses on the identification and management of sepsis, especially in the case of acute postoperative fistulas. In this acute phase, the etiology of the fistula is often not important. </p><p>Fistula-associated abdominal sepsis (eg, intra-abdominal abscess, gastrointestinal perforation, or subcutaneous infection) needs to be recognized and promptly treated with antibiotics, percutaneous catheter drainage, and/or operative drainage or source control. Prompt treatment of abdominal sepsis will reduce the risk of mortality as well as progressive organ dysfunction [<a href="#rid28">28,29</a>]. Infection and sepsis account for over 70 percent of mortality associated with these fistulas [<a href="#rid13">13</a>]. </p><p class="headingAnchor" id="H3805639931"><span class="h2">Treatment of sepsis</span><span class="headingEndMark"> — </span>Patients who have diffuse peritonitis or evidence of free gastrointestinal perforation on imaging studies require urgent surgical exploration. It is rare that an enterocutaneous fistula can be resected or closed primarily in the acute phase, particularly if it is a postoperative complication. Thus, operative sepsis control should focus on infection drainage and exteriorization of any leaking small or large intestine. A common mistake is to repair or primarily redo the anastomosis in the infected field in order to avoid a stoma. No new anastomoses should be created in a critically ill patient or in the presence of significant intra-abdominal contamination. Diversion of the fecal stream by ostomy is often required and is the preferred approach. In the setting of acute sepsis, diversion is highly recommended to prevent further complications. Resection of healthy bowel that may be involved in an inflammatory process should also be avoided. </p><p>Hemodynamically stable patients without diffuse peritonitis should undergo abdominopelvic computed tomography (CT) to identify any intra-abdominal source of sepsis, such as intra-abdominal abscess or fluid collection. Patients with a contained fluid collection or abscess may undergo image-guided percutaneous drainage (ultrasound or CT) [<a href="#rid30">30</a>]. Drainage is usually performed through the anterior abdominal wall. However, abscesses deep in the pelvis or obscured by other organs may be accessed with a variety of other approaches, including transgastric, transrectal, transvaginal, and transgluteal [<a href="#rid18">18</a>]. The drainage catheter is usually left in place until output is less than 10 mL in 24 hours or until definitive fistula surgery. Catheter fistulogram during this period permits assessment of resolution of the abscess cavity and determination of direct communication of drainage catheter with the bowel. Operative drainage is needed if sepsis does not resolve with catheter drainage. </p><p>Antibiotic management in septic patients should follow the Surviving Sepsis Guidelines [<a href="#rid31">31</a>]. Once source control is obtained by operative or catheter drainage, empirical antibiotics should be discontinued after another five to seven days. (See  <a class="medical medical_review" href="/d/html/101694.html" rel="external">"Antimicrobial approach to intra-abdominal infections in adults", section on 'Duration of therapy'</a>.)</p><p>Antibiotic management in nonseptic patients with an enterocutaneous fistula is controversial. Because no studies have demonstrated improved outcomes with antibiotic therapy in these patients and there are increasing concerns for multidrug-resistant bacteria, we do not suggest routine antibiotic coverage for patients who are not septic and have no acute signs of infection. </p><p class="headingAnchor" id="H978499470"><span class="h2">Restoration of hemodynamic stability</span><span class="headingEndMark"> — </span>Treatment of sepsis in the acute phase also requires restoration of hemodynamic stability. Resuscitation with fluids, repletion of electrolytes, and restoration of normotension may be required on a case-by-case basis; some may require vasopressors in an intensive care unit (ICU) setting. (See  <a class="medical medical_review" href="/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults"</a>.)</p><p class="headingAnchor" id="H1344210606"><span class="h1">CHRONIC MANAGEMENT</span><span class="headingEndMark"> — </span>Chronic management of fistulas entails evaluation and treatment of fluid, electrolyte, and nutritional losses and specialized wound care to manage the intestinal effluent  (<a class="graphic graphic_table graphicRef57027" href="/d/graphic/57027.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef118853" href="/d/graphic/118853.html" rel="external">algorithm 1</a>). In those with high-output fistulas, drug therapies may be instituted to reduce fistula output. </p><p class="headingAnchor" id="H320290"><span class="h2">Fluid therapy</span><span class="headingEndMark"> — </span>Aggressive correction of hypovolemia and electrolyte loss should occur early in treatment. Hyponatremia, hypokalemia, and hypomagnesium are the most common electrolyte abnormalities. Ongoing fluid losses from moderate-output upper gastrointestinal fistulas should be replaced with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and potassium supplementation with serial measurements of serum electrolytes. The composition of replacement fluid should mimic that of fluid lost as much as possible  (<a class="graphic graphic_table graphicRef119174" href="/d/graphic/119174.html" rel="external">table 3</a>) [<a href="#rid32">32</a>]. Replacing fluid losses cc per cc may be necessary to help prevent dehydration and hypovolemia. </p><p>High-output fistulas may require direct electrolyte analysis of the fistula effluent to make an appropriate choice of replacement fluid. The St. Mark's Intestinal Failure Unit has created a worksheet to help calculate daily losses for patients with high-output fistulas [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults"</a> and  <a class="medical medical_review" href="/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults"</a>.)</p><p>Duodenal or pancreatic fistulas may require bicarbonate replacement to prevent metabolic acidosis. (See  <a class="medical medical_review" href="/d/html/2291.html" rel="external">"Approach to the adult with metabolic acidosis", section on 'Overview of therapy'</a>.)</p><p class="headingAnchor" id="H320386"><span class="h2">Nutritional support</span><span class="headingEndMark"> — </span>Nutritional optimization is critical to successful resolution of the fistula. Data demonstrate that nutritionally optimized patients with serum albumin of ≥4 mg/dL have lower mortality from surgical interventions [<a href="#rid34">34</a>]. In addition, the spontaneous healing rate of the fistula improves from 7 to 81 percent when nutrition is optimized [<a href="#rid35">35</a>]. The nutritional needs of a patient with an enterocutaneous or enteroatmospheric fistula are met with enteral feeding, parenteral feeding, or a combination of the two. The decision is primarily dependent upon fistula output  (<a class="graphic graphic_algorithm graphicRef118853" href="/d/graphic/118853.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H934933750"><span class="h3">Nutritional goals</span><span class="headingEndMark"> — </span>Depending on the amount of output, the baseline energy requirement for a patient with an enterocutaneous or enteroatmospheric fistula may be 1 to 2.5 times that of a healthy adult [<a href="#rid36">36</a>]. The requirement may be even higher for patients with ongoing infection, large open abdominal wounds, and high-output fistulas. </p><p>The estimated nutrition needs for a patient with a low-output fistula range from 20 to 30 kcal/kg per day of total caloric intake and 1 to 1.5 g/kg per day of protein intake. Those with a high-output fistula require 25 to 35 kcal/kg per day of total caloric intake and 1.5 to 2.5 g/kg per day of protein intake (due to up to 75 g of protein loss in the effluent) [<a href="#rid6">6</a>]. Required doses of vitamins and trace elements, such as <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>, zinc, copper, and <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a>, which promote healing, may be increased substantially [<a href="#rid6">6</a>]. The addition of fish oil or omega-3 fatty acids has also been shown to improve immune function [<a href="#rid37">37</a>] after severe injury [<a href="#rid38">38</a>], abdominal operation [<a href="#rid39">39</a>], and in patients in the intensive care unit [<a href="#rid40">40</a>]. There are no trials directly investigating the effect of omega-3 fatty acid nutritional supplements specifically in the treatment of enterocutaneous fistula. </p><p>It may be necessary to carefully calculate the composition and quantity of daily output to determine repletion requirements. Ongoing assessment of the patient's nutritional, electrolyte, and fluid status may be necessary for patients with high-output fistulas [<a href="#rid41">41</a>]. Serum albumin, prealbumin, transferrin, C-reactive protein, weight, and anthropometrics should be followed over time [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H1624032905"><span class="h3">Low-output fistulas (&lt;200 mL/day)</span><span class="headingEndMark"> — </span>Enteral feeding is always preferred to <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> because this route preserves the intestinal mucosal barrier and has positive effects on immunologic and hormonal gut functions. However, although the patient may eat well, absorption of nutrition may be compromised by the fistula to the degree determined by its output and location. With proximal fistulization (jejunal), the patient may not have adequate absorptive capacity in the functioning intestines to maintain nutrition. Additionally, the output from the fistula may increase in quantity with enteral feeding and become excessive, requiring fluid supplementation. For patients trying enteral feeding, the goal enteric output is &lt;1.5 L/day. The following is our protocol for managing nutrition in patients with low-output fistulas  (<a class="graphic graphic_algorithm graphicRef118853" href="/d/graphic/118853.html" rel="external">algorithm 1</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>After the patient has been stabilized and sepsis treated, we generally try a short period of bowel rest (days) to see if the fistula output would reduce and/or if the fistula would spontaneously close. During this brief period of bowel rest, the patient may or may not need total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> (TPN) depending on his/her baseline nutritional status. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fistula output does not decrease with bowel rest and the fistula does not close, the patient is then started on an oral diet while we continue to monitor and manage output. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the fistula output increases substantially with oral diet, we will generally stop oral diet and start TPN to see if that decreases output. TPN has been known to reduce fistula output [<a href="#rid6">6</a>]. </p><p></p><p class="headingAnchor" id="H2780053700"><span class="h3">Moderate- or high-output fistulas (&gt;200 mL/day)</span><span class="headingEndMark"> — </span>Patients with moderate- to high-output enteric fistulas may be intolerant to oral nutrition secondary to inability to control sepsis, poor absorption, greater fluid and nutrient loss from fistula output, or difficulty with infection or excoriation of the skin. </p><p>Output from the fistula may decrease with an elemental diet [<a href="#rid42">42</a>]. One specialized intestinal failure unit reported lowering fistula output by limiting the intake of low-sodium fluids (free fluids) to 500 mL/day and encouraging the patient to drink an electrolyte solution containing high concentrations of sodium and glucose (up to 1000 mL per day) [<a href="#rid43">43</a>]. Drug therapies may also be successful, including anticathartics (eg, <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a>, diphenoxylate, <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a>), histamine-2 receptor antagonists and proton pump inhibitors [<a href="#rid21">21</a>], <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a>, and somatostatin analogues. (See <a class="local">'Fistula output reduction'</a> below.) </p><p>In general, patients with output greater than 1.5 L/day, less than 75 cm of intestinal length prior to the fistula, or intestinal discontinuity may require parenteral nutritional supplementation. In these cases, <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> may be required exclusively or as an adjunct to oral nutrition. Parenteral nutritional support should be initiated slowly after correction of fluid, electrolyte, and vitamin deficits has been completed [<a href="#rid36">36,44,45</a>]. (See  <a class="medical medical_review" href="/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.) </p><p class="headingAnchor" id="H21349702"><span class="h2">Wound care</span><span class="headingEndMark"> — </span>The main goal in wound care is to protect the skin near the external fistula opening from the corrosive effects of the enteric or pancreatic contents and promote wound healing. Wound care for most low-output fistulas requires nothing more than a gauze cover. Moderate-output fistulas can be controlled with an ostomy appliance. The real challenge is management of high-output fistulas and enteroatmospheric fistulas.</p><p class="headingAnchor" id="H21349708"><span class="h3">Bag drainage</span><span class="headingEndMark"> — </span>Skin protection creams and effluent collection bags must be tailored to the unique characteristics of each fistula, but the principles are similar to those used in the care of a colostomy or ileostomy [<a href="#rid22">22</a>]. The assistance of a skilled enterostomal therapist is helpful. (See  <a class="medical medical_review" href="/d/html/1384.html" rel="external">"Ileostomy or colostomy care and complications"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>For enterocutaneous fistulas, a pouch should be placed around the fistula. The adjacent skin should be protected with semipermeable barrier dressing or other skin protectants. Wound protectors and wound managers may be used to minimize skin irritation and collect effluent as with surgical ostomy. (See  <a class="medical medical_review" href="/d/html/1384.html" rel="external">"Ileostomy or colostomy care and complications", section on 'Pouch systems and routine ostomy care'</a>.) </p><p></p><p class="bulletIndent1">Effluent from the fistula is often acidic and copious and can result in significant denudation and excoriation of the surrounding skin. Cellulitis or fungal infection is not uncommon with poorly controlled fistula output. Sophisticated pouching systems available at specialty centers that care for these patients can protect the skin, divert the effluent, and are key to allowing patients to function prior to surgery. Good pouching can convert an inflamed, painful wound into a functional stoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Control of intestinal contents from an enteroatmospheric fistula will minimize damage to the healing bed of granulation tissue until definitive closure of the fistula can be undertaken 6 to 12 months later. Management options include the creation of a "floating stoma" by sewing exposed bowel mucosa circumferentially to a plastic sheet that is used as an interface to attach the stoma appliance and be placed on the surface of the exposed bowel [<a href="#rid46">46</a>]. A similar technique has also been described using an abdominal closure device, progressively approximating and inverting the edges of the skin to convert an open wound to a pouchable stoma [<a href="#rid47">47</a>].</p><p></p><p class="headingAnchor" id="H3809179851"><span class="h3">Negative pressure wound therapy</span><span class="headingEndMark"> — </span>Although there are no high-quality studies comparing negative pressure wound therapy  (<a class="graphic graphic_figure graphicRef50588" href="/d/graphic/50588.html" rel="external">figure 1</a>) with traditional drainage bags, the use of negative pressure wound therapy in fistula management has become widespread because surgeons are familiar with the technology from its successful application to other problematic wounds [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/2881.html" rel="external">"Negative pressure wound therapy", section on 'Mechanism of action'</a>.)</p><p>While many case series reported that negative pressure wound therapy accelerated fistula closure [<a href="#rid49">49-51</a>], none reported improved rates of fistula closure. In a few case reports, negative pressure wound therapy led to new fistula formation [<a href="#rid52">52</a>]. Nevertheless, most would agree that negative pressure wound therapy may be effective for high-output fistulas and hard-to-pouch fistulas and may improve the patient's quality of life by protecting surrounding skin and gathering effluent [<a href="#rid6">6</a>]. </p><p>Negative pressure wound therapy can also simplify management of enteroatmospheric fistulas. Continuous suction of the fistula output minimizes contact time between intestinal fluid and exposed peritoneum by effectively controlling intestinal spillage. A useful technique for superficial enteroatmospheric fistulas is to intubate the fistulas and bring the tubes out perpendicularly through the sponge of the negative pressure dressing  (<a class="graphic graphic_picture graphicRef63582" href="/d/graphic/63582.html" rel="external">picture 2</a>) [<a href="#rid53">53</a>]. With this technique, the majority of intestinal effluent is collected in the tubes. The sponge serves as a stable rig that anchors the tubes, prevents dislodgement, and collects any residual fluid that might leak around the tubes. Care must be used when applying a negative pressure wound dressing in the setting of exposed but uninvolved bowel because the dressing can cause formation of additional fistulas, especially if fresh suture or staple lines in the bowel are exposed [<a href="#rid52">52,54</a>]. Additional protection can be provided by placing another layer of plastic or a biologic dressing between the bowel and the negative pressure sponge [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/2881.html" rel="external">"Negative pressure wound therapy", section on 'Enterocutaneous fistula'</a>.)</p><p class="headingAnchor" id="H1568914"><span class="h2">Fistula output reduction</span><span class="headingEndMark"> — </span>In patients with a high-output fistula, fistula output reduction is critical to simplifying fluid management, optimizing wound care, and enabling enteral nutrition. Anticathartics, somatostatin and analogues, antisecretories, and <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> have been used to reduce the output from intestinal fistulas, especially when the output exceeds 1.5 L/day  (<a class="graphic graphic_table graphicRef119176" href="/d/graphic/119176.html" rel="external">table 4</a>) [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H1569167"><span class="h3">Anticathartics</span><span class="headingEndMark"> — </span>Anticathartics such as <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> hydrochloride (Imodium) and <a class="drug drug_general" data-topicid="9370" href="/d/drug information/9370.html" rel="external">diphenoxylate-atropine</a> (Lomotil) may be used for diarrhea and high-output fistulas. Loperamide is available in 2 mg tablets over the counter, while diphenoxylate requires a prescription for 2.5 mg tablets. Patients should titrate the dosage to output, with a typical maximal dose of 16 mg of loperamide and 20 mg of diphenoxylate daily. Both are also available in liquid form, which may be more useful for patients with poor absorption. Both medications are best used approximately 20 minutes prior to the consumption of foods. </p><p>In a British intestinal failure unit, higher doses of <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> (up to 40 mg/day) and <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> (up to 240 mg/day) have been used to control otherwise refractory high-output fistulas [<a href="#rid13">13,43</a>]. </p><p>Opiates, such as <a class="drug drug_general" data-topicid="9721" href="/d/drug information/9721.html" rel="external">tincture of opium</a> and <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a>, have also been used for their anticathartic property to treat high-output fistulas [<a href="#rid32">32,56</a>].</p><p class="headingAnchor" id="H1569023"><span class="h3">Somatostatin and analogues</span><span class="headingEndMark"> — </span>Intestinal fistula output can be reduced with somatostatin and its analogues (eg, <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">octreotide</a>). Somatostatin reduces fistula output, but its clinical use is limited by a very short half-life. Octreotide, with a half-life of two hours, reduces pancreatic secretions and may facilitate absorption of water and electrolytes. Somatostatin and its analogues are generally renally cleared, so attention must be paid to renal function in these patients. </p><p>A systematic review identified eight trials and found that somatostatin analogues decrease the duration of enterocutaneous fistulas (weighted mean difference [WMD] -6.37 days, 95% CI -8.33 to -4.42) and duration of hospital stay (WMD -4.53 days, 95% CI -8.29 to -0.77) but did not increase the rate of spontaneous closure [<a href="#rid57">57</a>]. A separate review found similar results but noted that somatostatin had a more significant effect compared with somatostatin analogues [<a href="#rid58">58</a>]. <a class="drug drug_general" data-topicid="9714" href="/d/drug information/9714.html" rel="external">Octreotide</a> does not significantly reduce the need for operation in patients with Crohn disease fistulas [<a href="#rid59">59,60</a>]. Octreotide may adversely affect immune function as a result of growth hormone inhibition [<a href="#rid61">61,62</a>], but there are no clinical data to confirm this possibility. It is also important to keep in mind that if the patient has one of the barriers to spontaneous closure  (<a class="graphic graphic_table graphicRef76451" href="/d/graphic/76451.html" rel="external">table 5</a>), such as distal obstruction, octreotide will be futile and will delay the surgical procedure ultimately needed to obtain definitive closure. </p><p>Specialized centers typically try somatostatin analogues for three days in an effort to decrease output in a fistula that produces &gt;1 L/day. If the output decreases within those three days, the treatment is continued for a longer period of time [<a href="#rid13">13,43</a>]. </p><p class="headingAnchor" id="H212013966"><span class="h3">Antisecretories</span><span class="headingEndMark"> — </span>Proton pump inhibitors and histamine-2 receptor antagonists decrease the volume and acidity of gastric output and have been a part of standard drug treatment for high-output fistulas [<a href="#rid13">13</a>]. However, none of the acid reduction therapies have been shown to increase the rate of spontaneous fistula closure. </p><p class="headingAnchor" id="H759095444"><span class="h3">Cholestyramine</span><span class="headingEndMark"> — </span>For the uncommon bilioenteric fistula (eg, biliary-colonic), <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a> can be tried. It is available in powder form and dosed at 9 mg twice daily prior to meals. Each of these medications can be used for the treatment of diarrhea, with anecdotal evidence of decreased fistula output. In addition, patients with a fistula proximal to the terminal ileum may find reduced output after the addition of cholestyramine.</p><p class="headingAnchor" id="H2059358204"><span class="h1">NONOPERATIVE FISTULA CLOSURE</span><span class="headingEndMark"> — </span>The following nonsurgical treatments have been attempted to close or better control fistulas that do not close spontaneously. These methods are generally appropriate after the patient has been stabilized from the acute phase of an enterocutaneous or enteroatmospheric fistula. </p><p class="headingAnchor" id="H3036226951"><span class="h2">Endoscopic therapies</span><span class="headingEndMark"> — </span>Endoscopic therapy may be used to temporarily control the initial leak and limit infection, or as a definitive technique to close the fistula. The ability to intervene endoscopically is limited by endoscopic accessibility, which is determined by the location of the fistula. Fistulas in the esophagus, stomach, or colon are most amenable to endoscopic closure. Endoscopic manipulation may transiently increase intraluminal pressure, which may increase the risk of sepsis acutely. Thus, endoscopic therapy should only be pursued in stable, nonseptic patients by experienced providers. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Covered enteric stents</strong> have been used to treat early postoperative leaks of the colon and esophagus. Success rates vary by location, and a major concern of stenting is postplacement migration. When temporary stents were used to treat esophageal leaks, fistulas, and perforations, primary closure was achieved in 74 percent of patients, but stent migration rate occurred in 28 percent [<a href="#rid63">63</a>]. A study of 22 patients with colonic fistulas treated with stents noted a closure rate of 86 percent, but 69 percent of patients had diversion during the healing phase [<a href="#rid64">64</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endoscopic clipping</strong> of the intraluminal end of the fistula has also been successful. Over- or through-the-scope clips can be deployed endoscopically to close the internal opening of the fistula, preventing further soilage and promoting sealing of the fistula. Data are limited, but the largest series of 108 patients demonstrated a fistula closure rate of 42.9 percent at a median follow-up of about five months [<a href="#rid65">65</a>]. This technology is primarily used for acute fistulas and postoperative perforations and is not well suited for chronic fistulas. Potential complications include increasing the size of the fistula and causing further damage to surrounding tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fistula plugs</strong> can also be used to close the internal opening of the fistula. Plugs are generally made from porcine submucosa. Placement is also limited by endoscopic access, but case reports demonstrate success rates of up to 80 percent [<a href="#rid66">66-68</a>]. </p><p></p><p class="headingAnchor" id="H1141767733"><span class="h2">Fibrin sealant</span><span class="headingEndMark"> — </span>Small series also demonstrated successful fistula closure with multiple applications of fibrin glue. Placement of fibrin glue reduced median time to closure and increased rate of closure when compared with control groups [<a href="#rid69">69</a>]. Several applications may be necessary to achieve closure, and success is limited by the ability to treat the entire tract prior to drying of the glue. Ideal fistulas for fibrin glue treatment are long, narrow, low output, and devoid of distal obstruction and Crohn disease. </p><p class="headingAnchor" id="H2373251770"><span class="h1">OPERATIVE FISTULA CLOSURE</span><span class="headingEndMark"> — </span>Approximately one-third of enterocutaneous fistulas will close spontaneously within five to six weeks with conservative measures [<a href="#rid22">22-25</a>]. In one retrospective review of 79 patients with enterocutaneous fistulas, spontaneous closure occurred in 23 (29 percent) after a median of 39 days (range 7 to 163) [<a href="#rid70">70</a>]. </p><p>Predictors of spontaneous closure are given in the table  (<a class="graphic graphic_table graphicRef76451" href="/d/graphic/76451.html" rel="external">table 5</a>) [<a href="#rid34">34,71</a>]. Generally, fistulas with low output, long track, or proximal location are most likely to heal with conservative measures. Barriers to closure include distal obstruction, a short epithelialized fistula tract, infection, and malignancy [<a href="#rid21">21,71</a>]. Given that an enteroatmospheric fistula is an exposed hole in the bowel lumen without overlying skin or soft tissue, there should be no realistic expectation of its spontaneous closure. </p><p class="headingAnchor" id="H14456075"><span class="h2">Timing of surgery</span><span class="headingEndMark"> — </span>Patients with enterocutaneous fistulas that do not close with five to six weeks of nonoperative management are unlikely to heal spontaneously and will likely need surgery to definitively manage the fistula. In a review of patients with enterocutaneous fistulas, 90 percent of spontaneous closures occurred in the first month after resolution of sepsis and 10 percent during the second month [<a href="#rid21">21</a>]. No patients achieved spontaneous closure after two months [<a href="#rid70">70</a>]. </p><p>Although the timing of definitive surgery to close the fistula is a matter of judgment, surgery should be delayed as long as fistula output is gradually decreasing and the wound (or tract) shows signs of healing [<a href="#rid51">51</a>]. Surgery should generally be postponed for at least three to six months to allow for resolution of inflammation, which may reduce the risk of bowel injury. Specialized centers often delay the definitive surgery for 6 to 12 months  (<a class="graphic graphic_algorithm graphicRef118853" href="/d/graphic/118853.html" rel="external">algorithm 1</a>). </p><p>The presence of a fistula is usually associated with a severe inflammatory response that leads to dense adhesions, known as "obliterative peritonitis," which make early surgery hazardous [<a href="#rid34">34,72</a>]. Dense adhesions begin to form in the open abdominal wound after approximately one week of exposure and remain treacherous for at least six to eight weeks. In one study, the mortality rate associated with surgery between days 11 and 42 after presentation of the fistula (21 percent) was significantly higher than the mortality rate of either operating before day 11 (13 percent) or after day 42 (11 percent) [<a href="#rid34">34</a>]. Recurrence rates of postoperative fistula also appear to be higher with earlier surgery [<a href="#rid73">73</a>]. </p><p class="headingAnchor" id="H2675060934"><span class="h2">Preoperative preparation</span><span class="headingEndMark"> — </span>Before any definitive operative closure of an enterocutaneous fistula, the patient should be nutritionally replete, free of infection, and have supple, soft tissues adjacent to the fistula [<a href="#rid10">10,74</a>]. </p><p>Nutritionally, data suggest that raising serum albumin level to &gt;3.5 mg/dL reduces perioperative mortality rate to 0 percent [<a href="#rid34">34</a>]. Definitive surgical management of a fistula should also be delayed until the initial scar or incision is mobile and can be pinched between the examining thumb and index fingers, which signifies the existence of a plane between the skin/skin graft and underlying bowel [<a href="#rid75">75</a>].</p><p>Prior to surgery, abdominal computed tomography (CT) imaging should be repeated to rule out any residual intra-abdominal fluid collection or a distal obstruction and assess for evidence of Crohn disease, radiation enteritis, malignancy, or any other pathologies that could increase the likelihood of recurrence  (<a class="graphic graphic_table graphicRef76451" href="/d/graphic/76451.html" rel="external">table 5</a>). Fluoroscopic exams, such as small bowel follow-through series and fistulograms, image contrast passage through the fistula in real time, which may help define the fistula anatomy. In addition, contrast injected retrograde through the fistula, drain, or rectum may help identify distal disease (eg, obstruction, stricture, or tumor) that will need to be addressed at the time of surgery. Endoscopic evaluation of the distal colon should also be considered prior to surgery. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p>Patients should also be mentally prepared for the surgery. They should be forewarned that the recurrence rate after surgery for enterocutaneous fistula can be as high as 20 to 36 percent [<a href="#rid73">73</a>] and that a diverting stoma may be required. Prior to surgery, the surgeon should mark potential stoma sites, particularly in patients with Crohn disease or diverticular disease, and consider placing ureteral stents if colon mobilization is anticipated. (See  <a class="medical medical_review" href="/d/html/15026.html" rel="external">"Overview of surgical ostomy for fecal diversion", section on 'Preparation and counseling'</a> and  <a class="medical medical_review" href="/d/html/15182.html" rel="external">"Placement and management of indwelling ureteral stents", section on 'Prophylactic'</a>.)</p><p class="headingAnchor" id="H4077603165"><span class="h2">Surgical techniques</span><span class="headingEndMark"> — </span>The aim of the surgery is to eliminate the fistula, which usually requires resection of the segment of bowel that is the origin of the fistula, reestablishment of gastrointestinal continuity, and tension-free closure of the abdomen with well-vascularized soft tissue [<a href="#rid10">10</a>]. Fecal diversion and bowel rest during the postoperative healing period can be used to minimize recurrence. </p><p>Since studies evaluating surgical techniques for managing enterocutaneous fistulas are generally heterogeneous and of low quality [<a href="#rid76">76</a>], the surgical approach described below is derived from expert opinions and our clinical experience. </p><p class="headingAnchor" id="H5688308"><span class="h3">Incision and adhesiolysis</span><span class="headingEndMark"> — </span>For patients with an intact abdominal wall, the incision should be placed remote from prior incisions where bowel loops may be adherent to the abdominal wall. The incision should also preserve vascular supply to the soft tissue of the abdominal wall, which is critical to any successful complex abdominal wall reconstruction (eg, component separation). </p><p>Once the incision is made, lysis of adhesions is performed to free the abdominal wall circumferentially from adherent bowel. Expert surgeons recommend working laterally first to take down adhesions and deliver the bowel from the side of the abdomen least involved [<a href="#rid7">7,77</a>]. The adhesions are often dense, and the dissection should be slow and careful. The surgeon must be prepared to spend hours performing meticulous adhesiolysis and mobilizing the entire length of the gastrointestinal tract from the ligament of Treitz to the rectum, if necessary, to identify the fistula and approach it safely [<a href="#rid10">10</a>]. It is usually not advisable to schedule other major elective operations on the same day, because these demanding procedures often take all day. </p><p>During the surgery, the surgeon should identify normal areas of small bowel that are free from injury and primary disease where the fistula and any other pathology are found. In addition, there may be segments of bowel where serosal injuries or small iatrogenic full-thickness injury occurred during adhesiolysis. Each of these areas should be evaluated before decisions can be made about resection or repair based on the available bowel reserve. Issues with malabsorption and short bowel syndrome may occur with less than 100 cm of viable small bowel remaining, depending on whether the ileocecal valve is present and the remaining length of the colon. (See  <a class="medical medical_review" href="/d/html/4773.html" rel="external">"Management of short bowel syndrome in adults"</a>.)</p><p class="headingAnchor" id="H14456880"><span class="h3">Fistula resection</span><span class="headingEndMark"> — </span>Once the fistula and primary pathology (ie, source of infection/obstruction) have been clearly defined, the segment of bowel that contains the origin of the fistula is resected and gastrointestinal continuity reestablished. (See  <a class="medical medical_review" href="/d/html/86841.html" rel="external">"Bowel resection techniques"</a>.)</p><p>We suggest a segmental resection of the bowel containing the fistula, rather than a wedge resection of the fistula. In a large series of patients with fistulas, patients who underwent segmental resection of the primary disease had a significantly lower rate of fistula recurrence than patients who had wedge resection (18 versus 33 percent) [<a href="#rid73">73</a>]. For patients with Crohn disease, complete resection of the enterocutaneous fistula, as well as the adjacent diseased bowel, is necessary to prevent recurrence [<a href="#rid73">73</a>]. </p><p class="headingAnchor" id="H6056722"><span class="h3">Abdominal wall closure or reconstruction</span><span class="headingEndMark"> — </span>Once an enterocutaneous fistula is resected and gastrointestinal continuity restored, the abdomen should be closed using standard techniques, provided this will not result in undue tension. (See  <a class="medical medical_review" href="/d/html/4.html" rel="external">"Principles of abdominal wall closure"</a>.)</p><p>The goal of the definitive surgery in the management of enteroatmospheric fistulas, besides closing the fistula, is to reconstruct the abdominal wall with durable, well-vascularized tissue. A two-team approach has the advantage of providing a well-rested plastic surgeon focused on reconstruction after a long and tedious visceral dissection by the general surgery team [<a href="#rid10">10</a>]. Closure of large or complex abdominal wall defects associated with enteroatmospheric fistulas may require advancement flap techniques. One option for abdominal closure is the component separation technique, provided the rectus abdominis muscle remains intact [<a href="#rid78">78</a>]. Defects up to 10 cm in the upper abdomen, 20 cm in the midabdomen, and 8 cm in the lower abdomen can be closed using this technique. Other options may include random, pedicle, or free flaps with microvascular reconstruction. (See  <a class="medical medical_review" href="/d/html/3688.html" rel="external">"Overview of abdominal wall hernias in adults"</a> and  <a class="medical medical_review" href="/d/html/130470.html" rel="external">"Overview of component separation"</a>.) </p><p class="headingAnchor" id="H1713148023"><span class="h1">MORTALITY</span><span class="headingEndMark"> — </span>Historically, mortality rates after developing an enterocutaneous fistula were as high as 65 percent in some series. Sepsis is responsible for 70 percent of case fatalities [<a href="#rid13">13</a>]. However, specialized care centers have been able to reduce morbidity and mortality greatly. With modern management strategies, most modern series report a mortality rate of 10 to 20 percent  (<a class="graphic graphic_table graphicRef54412" href="/d/graphic/54412.html" rel="external">table 6</a>) [<a href="#rid7">7,10,13,19,59,70,79</a>]. </p><p class="headingAnchor" id="H287038919"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/17214.html" rel="external">"Patient education: Enteric fistula (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H322535"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>A fistula is an abnormal connection between two epithelialized hollow spaces or organs. Enterocutaneous fistulas communicate between the lumen of the gastrointestinal tract and the skin. Enteroatmospheric fistulas communicate between the lumen of the gastrointestinal tract and the wound of an open abdomen. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The majority of enterocutaneous fistulas occur in the postoperative setting, usually as a result of a bowel anastomotic leak or missed enterotomy. Approximately 20 to 30 percent of enterocutaneous fistulas arise spontaneously, most commonly due to Crohn disease. Other etiologies of spontaneous enteric fistula formation and persistence include <strong>f</strong>oreign body, <strong>r</strong>adiation, <strong>i</strong>nflammation or <strong>i</strong>nfection (eg, tuberculosis, actinomycosis), <strong>e</strong>pithelialization, <strong>n</strong>eoplasia, and <strong>d</strong>istal obstruction  (<a class="graphic graphic_table graphicRef76953" href="/d/graphic/76953.html" rel="external">table 1</a>). (See <a class="local">'Etiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common clinical presentation of an enterocutaneous fistula is in a postoperative patient who fails to recover normally from abdominal surgery. The patient often presents first with abdominal symptoms and signs of bowel obstruction. A wound infection is then typically recognized 7 to 10 days postoperatively, and following incisional drainage, enteric contents appear in the surgical wound. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By definition, an enteroatmospheric fistula can only be diagnosed in a patient with an open abdomen. The diagnosis can be confirmed by the presence of enteric contents draining from an opening in a segment of bowel in the open abdominal wound. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The organ of origin of an enterocutaneous or enteroatmospheric fistula is often not defined until imaging studies can be performed. We prefer abdominal computed tomography (CT) as the initial study for patients suspected to have an enterocutaneous or enteroatmospheric fistula, but only after the patient has been stabilized and sepsis treated. Other methods of identifying and characterizing enteric fistulas include gastrointestinal contrast studies, a fistulogram, and enteric administration of dye (eg, <a class="drug drug_general" data-topicid="9088" href="/d/drug information/9088.html" rel="external">indigo carmine</a>, <a class="drug drug_general" data-topicid="9636" href="/d/drug information/9636.html" rel="external">methylene blue</a>, charcoal). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute management of enterocutaneous and enteroatmospheric fistulas focuses on fluid therapy to correct volume and electrolyte deficits and treatment of infection/sepsis  (<a class="graphic graphic_algorithm graphicRef118853" href="/d/graphic/118853.html" rel="external">algorithm 1</a>). In this acute phase, the etiology of the fistula is often not important. Fistula-associated abdominal sepsis (eg, intra-abdominal abscess, gastrointestinal perforation, or subcutaneous infection) needs to be recognized and promptly treated with antibiotics, percutaneous catheter drainage, and/or operative drainage or source control. However, we suggest against routine antibiotic coverage for patients with a nonseptic enterocutaneous or enteroatmospheric fistula (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Acute management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic management of enterocutaneous and enteroatmospheric fistulas entails evaluation and treatment of fluid, electrolyte, and nutritional losses, and specialized wound care to manage the intestinal effluent  (<a class="graphic graphic_table graphicRef57027" href="/d/graphic/57027.html" rel="external">table 2</a> and <a class="graphic graphic_algorithm graphicRef118853" href="/d/graphic/118853.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with low- and high-output fistulas have different caloric and nutritional goals. (See <a class="local">'Nutritional goals'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a low-output fistula (&lt;200 mL/day), a trial of bowel rest for several days after initial fluid and electrolyte resuscitation  (<a class="graphic graphic_table graphicRef119174" href="/d/graphic/119174.html" rel="external">table 3</a>) and sepsis control may lead to spontaneous closure of the fistula. (See <a class="local">'Low-output fistulas (&lt;200 mL/day)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with a low-output fistula that does not close with bowel rest, oral diet should be started. If the fistula output increases with oral diet, and for patients with a moderate- or high-output fistula (&gt;200 mL/day), medical therapies to reduce fistula output may be instituted with the goal of limiting output to &lt;1.5 L/day. Choices of such medications include anticathartics, somatostatins and analogues, antisecretories, and <a class="drug drug_general" data-topicid="9258" href="/d/drug information/9258.html" rel="external">cholestyramine</a>  (<a class="graphic graphic_table graphicRef119176" href="/d/graphic/119176.html" rel="external">table 4</a>). (See <a class="local">'Fistula output reduction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with fistula output &gt;1.5 L/day, less than 75 cm of intestinal length prior to the fistula, or intestinal discontinuity, total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> is required, either exclusively or to supplemental enteral nutrition. (See <a class="local">'Moderate- or high-output fistulas (&gt;200 mL/day)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately one-third of fistulas heal spontaneously with conservative measures within five to six weeks. For patients with a persistent enterocutaneous or enteroatmospheric fistula, definitive surgical fistula closure is required but should be delayed for at least three to six months from the inciting event. High-volume centers often delay definitive operations for 6 to 12 months  (<a class="graphic graphic_algorithm graphicRef118853" href="/d/graphic/118853.html" rel="external">algorithm 1</a>). Before consideration of definitive operative repair of fistulas, patients should be nutritionally replete, free of infection, and have supple soft tissues adjacent to the fistula. (See <a class="local">'Operative fistula closure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The goals of definitive surgery are to resect the fistula, reestablish gastrointestinal continuity, and provide a tension-free closure of the abdomen with well-vascularized soft tissue. We suggest a segmental resection of the bowel containing the fistula, rather than a wedge resection of the fistula (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Segmental bowel resection is associated with a lower recurrence rate. (See <a class="local">'Surgical techniques'</a> above and <a class="local">'Fistula resection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modern care of enterocutaneous/enteroatmospheric fistulas, often provided at specialized centers, has reduced the mortality rate from 65 percent to 10 to 20 percent. (See <a class="local">'Mortality'</a> above.)</p><p></p><p class="headingAnchor" id="H532042641"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge William Schecter, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Teixeira PG, Inaba K, Dubose J, et al. Enterocutaneous fistula complicating trauma laparotomy: a major resource burden. Am Surg 2009; 75:30.</a></li><li><a class="nounderline abstract_t">Wercka J, Cagol PP, Melo AL, et al. Epidemiology and outcome of patients with postoperative abdominal fistula. Rev Col Bras Cir 2016; 43:117.</a></li><li><a class="nounderline abstract_t">Michelassi F, Stella M, Balestracci T, et al. Incidence, diagnosis, and treatment of enteric and colorectal fistulae in patients with Crohn's disease. Ann Surg 1993; 218:660.</a></li><li><a class="nounderline abstract_t">Annibali R, Pietri P. Fistulous complications of Crohn's disease. Int Surg 1992; 77:19.</a></li><li><a class="nounderline abstract_t">Brooks NE, Idrees JJ, Steinhagen E, et al. The impact of enteric fistulas on US hospital systems. Am J Surg 2021; 221:26.</a></li><li><a class="nounderline abstract_t">Gribovskaja-Rupp I, Melton GB. Enterocutaneous Fistula: Proven Strategies and Updates. Clin Colon Rectal Surg 2016; 29:130.</a></li><li><a class="nounderline abstract_t">Osborn C, Fischer JE. How I do it: gastrointestinal cutaneous fistulas. J Gastrointest Surg 2009; 13:2068.</a></li><li><a class="nounderline abstract_t">Burlew CC, Moore EE, Cuschieri J, et al. Sew it up! A Western Trauma Association multi-institutional study of enteric injury management in the postinjury open abdomen. J Trauma 2011; 70:273.</a></li><li><a class="nounderline abstract_t">Hu D, Ren J, Wang G, et al. Persistent inflammation-immunosuppression catabolism syndrome, a common manifestation of patients with enterocutaneous fistula in intensive care unit. J Trauma Acute Care Surg 2014; 76:725.</a></li><li><a class="nounderline abstract_t">Schecter WP, Hirshberg A, Chang DS, et al. Enteric fistulas: principles of management. J Am Coll Surg 2009; 209:484.</a></li><li><a class="nounderline abstract_t">Majercik S, Kinikini M, White T. Enteroatmospheric fistula: from soup to nuts. Nutr Clin Pract 2012; 27:507.</a></li><li><a class="nounderline abstract_t">Bradley MJ, Dubose JJ, Scalea TM, et al. Independent predictors of enteric fistula and abdominal sepsis after damage control laparotomy: results from the prospective AAST Open Abdomen registry. JAMA Surg 2013; 148:947.</a></li><li><a class="nounderline abstract_t">Hollington P, Mawdsley J, Lim W, et al. An 11-year experience of enterocutaneous fistula. Br J Surg 2004; 91:1646.</a></li><li><a class="nounderline abstract_t">Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002; 122:875.</a></li><li><a class="nounderline abstract_t">Evenson AR, Fischer JE. Current management of enterocutaneous fistula. J Gastrointest Surg 2006; 10:455.</a></li><li><a class="nounderline abstract_t">Alexander ES, Weinberg S, Clark RA, Belkin RD. Fistulas and sinus tracts: radiographic evaluation, management, and outcome. Gastrointest Radiol 1982; 7:135.</a></li><li><a class="nounderline abstract_t">Kwon SH, Oh JH, Kim HJ, et al. Interventional management of gastrointestinal fistulas. Korean J Radiol 2008; 9:541.</a></li><li><a class="nounderline abstract_t">Schein M, Decker GA. Gastrointestinal fistulas associated with large abdominal wall defects: experience with 43 patients. Br J Surg 1990; 77:97.</a></li><li><a class="nounderline abstract_t">Irving M, White R, Tresadern J. Three years' experience with an intestinal failure unit. Ann R Coll Surg Engl 1985; 67:2.</a></li><li><a class="nounderline abstract_t">Sansoni B, Irving M. Small bowel fistulas. World J Surg 1985; 9:897.</a></li><li><a class="nounderline abstract_t">Reber HA, Roberts C, Way LW, Dunphy JE. Management of external gastrointestinal fistulas. Ann Surg 1978; 188:460.</a></li><li><a class="nounderline abstract_t">Martinez JL, Luque-de-Leon E, Mier J, et al. Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes. World J Surg 2008; 32:436.</a></li><li><a class="nounderline abstract_t">Aguirre A, Fischer JE, Welch CE. The role of surgery and hyperalimentation in therapy of gastrointestinal-cutaneous fistulae. Ann Surg 1974; 180:393.</a></li><li><a class="nounderline abstract_t">Prickett D, Montgomery R, Cheadle WG. External fistulas arising from the digestive tract. South Med J 1991; 84:736.</a></li><li><a class="nounderline abstract_t">Schein M. What's new in postoperative enterocutaneous fistulas? World J Surg 2008; 32:336.</a></li><li><a class="nounderline abstract_t">Rahbour G, Gabe SM, Ullah MR, et al. Seven-year experience of enterocutaneous fistula with univariate and multivariate analysis of factors associated with healing: development of a validated scoring system. Colorectal Dis 2013; 15:1162.</a></li><li><a class="nounderline abstract_t">Li J, Ren J, Zhu W, et al. Management of enterocutaneous fistulas: 30-year clinical experience. Chin Med J (Engl) 2003; 116:171.</a></li><li><a class="nounderline abstract_t">Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.</a></li><li><a class="nounderline abstract_t">Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368.</a></li><li><a class="nounderline abstract_t">Fulcher AS, Turner MA. Percutaneous drainage of enteric-related abscesses. Gastroenterologist 1996; 4:276.</a></li><li><a class="nounderline abstract_t">Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017; 43:304.</a></li><li><a class="nounderline abstract_t">Bleier JI, Hedrick T. Metabolic support of the enterocutaneous fistula patient. Clin Colon Rectal Surg 2010; 23:142.</a></li><li><a class="nounderline abstract_t">Samad S, Anele C, Akhtar M, Doughan S. Implementing a Pro-forma for Multidisciplinary Management of an Enterocutaneous Fistula: A Case Study. Ostomy Wound Manage 2015; 61:46.</a></li><li><a class="nounderline abstract_t">Fazio VW, Coutsoftides T, Steiger E. Factors influencing the outcome of treatment of small bowel cutaneous fistula. World J Surg 1983; 7:481.</a></li><li><a class="nounderline abstract_t">CHAPMAN R, FORAN R, DUNPHY JE. MANAGEMENT OF INTESTINAL FISTULAS. Am J Surg 1964; 108:157.</a></li><li><a class="nounderline abstract_t">Polk TM, Schwab CW. Metabolic and nutritional support of the enterocutaneous fistula patient: a three-phase approach. World J Surg 2012; 36:524.</a></li><li><a class="nounderline abstract_t">Kudsk KA. Immunonutrition in surgery and critical care. Annu Rev Nutr 2006; 26:463.</a></li><li><a class="nounderline abstract_t">Kudsk KA, Minard G, Croce MA, et al. A randomized trial of isonitrogenous enteral diets after severe trauma. An immune-enhancing diet reduces septic complications. Ann Surg 1996; 224:531.</a></li><li><a class="nounderline abstract_t">Schilling J, Vranjes N, Fierz W, et al. Clinical outcome and immunology of postoperative arginine, omega-3 fatty acids, and nucleotide-enriched enteral feeding: a randomized prospective comparison with standard enteral and low calorie/low fat i.v. solutions. Nutrition 1996; 12:423.</a></li><li><a class="nounderline abstract_t">Bower RH, Cerra FB, Bershadsky B, et al. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995; 23:436.</a></li><li><a class="nounderline abstract_t">Lloyd DA, Gabe SM, Windsor AC. Nutrition and management of enterocutaneous fistula. Br J Surg 2006; 93:1045.</a></li><li><a class="nounderline abstract_t">Bury KD, Stephens RV, Randall HT. Use of a chemically defined, liquid, elemental diet for nutritional management of fistulas of the alimentary tract. Am J Surg 1971; 121:174.</a></li><li><a class="nounderline abstract_t">Datta V, Engledow A, Chan S, et al. The management of enterocutaneous fistula in a regional unit in the United kingdom: a prospective study. Dis Colon Rectum 2010; 53:192.</a></li><li><a class="nounderline abstract_t">Dudrick SJ, Maharaj AR, McKelvey AA. Artificial nutritional support in patients with gastrointestinal fistulas. World J Surg 1999; 23:570.</a></li><li><a class="nounderline abstract_t">Stanga Z, Brunner A, Leuenberger M, et al. Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment. Eur J Clin Nutr 2008; 62:687.</a></li><li><a class="nounderline abstract_t">Subramaniam MH, Liscum KR, Hirshberg A. The floating stoma: a new technique for controlling exposed fistulae in abdominal trauma. J Trauma 2002; 53:386.</a></li><li><a class="nounderline abstract_t">Freund MR, Reissman P, Spira RM, Topaz M. Innovative approach to open abdomen: converting an enteroatmospheric fistula into an easily manageable stoma. BMJ Case Rep 2020; 13.</a></li><li><a class="nounderline abstract_t">Boulanger K, Lemaire V, Jacquemin D. Vacuum-assisted closure of enterocutaneous fistula. Acta Chir Belg 2007; 107:703.</a></li><li><a class="nounderline abstract_t">Cro C, George KJ, Donnelly J, et al. Vacuum assisted closure system in the management of enterocutaneous fistulae. Postgrad Med J 2002; 78:364.</a></li><li><a class="nounderline abstract_t">Banwell P, Withey S, Holten I. The use of negative pressure to promote healing. Br J Plast Surg 1998; 51:79.</a></li><li><a class="nounderline abstract_t">Wainstein DE, Fernandez E, Gonzalez D, et al. Treatment of high-output enterocutaneous fistulas with a vacuum-compaction device. A ten-year experience. World J Surg 2008; 32:430.</a></li><li><a class="nounderline abstract_t">Fischer JE. A cautionary note: the use of vacuum-assisted closure systems in the treatment of gastrointestinal cutaneous fistula may be associated with higher mortality from subsequent fistula development. Am J Surg 2008; 196:1.</a></li><li><a class="nounderline abstract_t">Al-Khoury G, Kaufman D, Hirshberg A. Improved control of exposed fistula in the open abdomen. J Am Coll Surg 2008; 206:397.</a></li><li><a class="nounderline abstract_t">Rao M, Burke D, Finan PJ, Sagar PM. The use of vacuum-assisted closure of abdominal wounds: a word of caution. Colorectal Dis 2007; 9:266.</a></li><li><a class="nounderline abstract_t">Jamshidi R, Schecter WP. Biological dressings for the management of enteric fistulas in the open abdomen: a preliminary report. Arch Surg 2007; 142:793.</a></li><li><a class="nounderline abstract_t">Parli SE, Pfeifer C, Oyler DR, et al. Redefining "bowel regimen": Pharmacologic strategies and nutritional considerations in the management of small bowel fistulas. Am J Surg 2018; 216:351.</a></li><li><a class="nounderline abstract_t">Coughlin S, Roth L, Lurati G, Faulhaber M. Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis. World J Surg 2012; 36:1016.</a></li><li><a class="nounderline abstract_t">Rahbour G, Siddiqui MR, Ullah MR, et al. A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas. Ann Surg 2012; 256:946.</a></li><li><a class="nounderline abstract_t">Draus JM Jr, Huss SA, Harty NJ, et al. Enterocutaneous fistula: are treatments improving? Surgery 2006; 140:570.</a></li><li><a class="nounderline abstract_t">Alivizatos V, Felekis D, Zorbalas A. Evaluation of the effectiveness of octreotide in the conservative treatment of postoperative enterocutaneous fistulas. Hepatogastroenterology 2002; 49:1010.</a></li><li><a class="nounderline abstract_t">Wiedermann CJ, Reinisch N, Braunsteiner H. Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood 1993; 82:954.</a></li><li><a class="nounderline abstract_t">Lattuada D, Casnici C, Crotta K, et al. Inhibitory effect of pasireotide and octreotide on lymphocyte activation. J Neuroimmunol 2007; 182:153.</a></li><li><a class="nounderline abstract_t">El Hajj II, Imperiale TF, Rex DK, et al. Treatment of esophageal leaks, fistulae, and perforations with temporary stents: evaluation of efficacy, adverse events, and factors associated with successful outcomes. Gastrointest Endosc 2014; 79:589.</a></li><li><a class="nounderline abstract_t">Lamazza A, Fiori E, Schillaci A, et al. Recurrent rectovaginal fistula: treatment with self-expanding metal stents. Endoscopy 2015; 47 Suppl 1 UCTN:E149.</a></li><li><a class="nounderline abstract_t">Haito-Chavez Y, Law JK, Kratt T, et al. International multicenter experience with an over-the-scope clipping device for endoscopic management of GI defects (with video). Gastrointest Endosc 2014; 80:610.</a></li><li><a class="nounderline abstract_t">Truong S, Böhm G, Klinge U, et al. Results after endoscopic treatment of postoperative upper gastrointestinal fistulas and leaks using combined Vicryl plug and fibrin glue. Surg Endosc 2004; 18:1105.</a></li><li><a class="nounderline abstract_t">Böhm G, Mossdorf A, Klink C, et al. Treatment algorithm for postoperative upper gastrointestinal fistulas and leaks using combined vicryl plug and fibrin glue. Endoscopy 2010; 42:599.</a></li><li><a class="nounderline abstract_t">Filgate R, Thomas A, Ballal M. Treatment of foregut fistula with biologic plugs. Surg Endosc 2015; 29:2006.</a></li><li><a class="nounderline abstract_t">Wu X, Ren J, Gu G, et al. Autologous platelet rich fibrin glue for sealing of low-output enterocutaneous fistulas: an observational cohort study. Surgery 2014; 155:434.</a></li><li><a class="nounderline abstract_t">Visschers RG, van Gemert WG, Winkens B, et al. Guided treatment improves outcome of patients with enterocutaneous fistulas. World J Surg 2012; 36:2341.</a></li><li><a class="nounderline abstract_t">Campos AC, Andrade DF, Campos GM, et al. A multivariate model to determine prognostic factors in gastrointestinal fistulas. J Am Coll Surg 1999; 188:483.</a></li><li><a class="nounderline abstract_t">Hill GL. Operative strategy in the treatment of enterocutaneous fistulas. World J Surg 1983; 7:495.</a></li><li><a class="nounderline abstract_t">Lynch AC, Delaney CP, Senagore AJ, et al. Clinical outcome and factors predictive of recurrence after enterocutaneous fistula surgery. Ann Surg 2004; 240:825.</a></li><li><a class="nounderline abstract_t">Becker HP, Willms A, Schwab R. Small bowel fistulas and the open abdomen. Scand J Surg 2007; 96:263.</a></li><li><a class="nounderline abstract_t">Jernigan TW, Fabian TC, Croce MA, et al. Staged management of giant abdominal wall defects: acute and long-term results. Ann Surg 2003; 238:349.</a></li><li><a class="nounderline abstract_t">Owen RM, Love TP, Perez SD, et al. Definitive surgical treatment of enterocutaneous fistula: outcomes of a 23-year experience. JAMA Surg 2013; 148:118.</a></li><li><a class="nounderline abstract_t">Marinis A, Gkiokas G, Argyra E, et al. "Enteroatmospheric fistulae"--gastrointestinal openings in the open abdomen: a review and recent proposal of a surgical technique. Scand J Surg 2013; 102:61.</a></li><li><a class="nounderline abstract_t">Shestak KC, Edington HJ, Johnson RR. The separation of anatomic components technique for the reconstruction of massive midline abdominal wall defects: anatomy, surgical technique, applications, and limitations revisited. Plast Reconstr Surg 2000; 105:731.</a></li><li class="breakAll">Fischer JE, Evenson AR. Gastrointestinal-cutanous fistulae. In: Mastery of Surgery, 5th, Fischer JE, Bland KI (Eds), Lippincott, Philadelphia 2007. Vol 2, p.1401.</li></ol></div><div id="topicVersionRevision">Topic 15157 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19213393" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Enterocutaneous fistula complicating trauma laparotomy: a major resource burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27275593" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Epidemiology and outcome of patients with postoperative abdominal fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8239781" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence, diagnosis, and treatment of enteric and colorectal fistulae in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1577575" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fistulous complications of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32778398" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The impact of enteric fistulas on US hospital systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27247538" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Enterocutaneous Fistula: Proven Strategies and Updates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19506977" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : How I do it: gastrointestinal cutaneous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307721" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Sew it up! A Western Trauma Association multi-institutional study of enteric injury management in the postinjury open abdomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553541" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Persistent inflammation-immunosuppression catabolism syndrome, a common manifestation of patients with enterocutaneous fistula in intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19801322" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Enteric fistulas: principles of management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683566" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Enteroatmospheric fistula: from soup to nuts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23965658" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Independent predictors of enteric fistula and abdominal sepsis after damage control laparotomy: results from the prospective AAST Open Abdomen registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505866" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An 11-year experience of enterocutaneous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11910338" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16504896" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Current management of enterocutaneous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7084596" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Fistulas and sinus tracts: radiographic evaluation, management, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19039271" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interventional management of gastrointestinal fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137358" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gastrointestinal fistulas associated with large abdominal wall defects: experience with 43 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3917641" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Three years' experience with an intestinal failure unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4082611" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Small bowel fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/697430" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Management of external gastrointestinal fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057983" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Systematic management of postoperative enterocutaneous fistulas: factors related to outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4213479" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The role of surgery and hyperalimentation in therapy of gastrointestinal-cutaneous fistulae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2052964" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : External fistulas arising from the digestive tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18235985" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : What's new in postoperative enterocutaneous fistulas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23869525" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Seven-year experience of enterocutaneous fistula with univariate and multivariate analysis of factors associated with healing: development of a validated scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775223" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Management of enterocutaneous fistulas: 30-year clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158437" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794169" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Early goal-directed therapy in the treatment of severe sepsis and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8957100" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Percutaneous drainage of enteric-related abscesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28101605" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21886463" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Metabolic support of the enterocutaneous fistula patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26061406" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Implementing a Pro-forma for Multidisciplinary Management of an Enterocutaneous Fistula: A Case Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6624123" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Factors influencing the outcome of treatment of small bowel cutaneous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14195208" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : MANAGEMENT OF INTESTINAL FISTULAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22033622" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Metabolic and nutritional support of the enterocutaneous fistula patient: a three-phase approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704351" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Immunonutrition in surgery and critical care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857857" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A randomized trial of isonitrogenous enteral diets after severe trauma. An immune-enhancing diet reduces septic complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8875537" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical outcome and immunology of postoperative arginine, omega-3 fatty acids, and nucleotide-enriched enteral feeding: a randomized prospective comparison with standard enteral and low calorie/low fat i.v. solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7874893" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16804873" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Nutrition and management of enterocutaneous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4993224" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Use of a chemically defined, liquid, elemental diet for nutritional management of fistulas of the alimentary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20087095" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The management of enterocutaneous fistula in a regional unit in the United kingdom: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10227926" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Artificial nutritional support in patients with gastrointestinal fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17700652" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12169956" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The floating stoma: a new technique for controlling exposed fistulae in abdominal trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32847870" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Innovative approach to open abdomen: converting an enteroatmospheric fistula into an easily manageable stoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18274191" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Vacuum-assisted closure of enterocutaneous fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12151694" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vacuum assisted closure system in the management of enterocutaneous fistulae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577325" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The use of negative pressure to promote healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17899253" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Treatment of high-output enterocutaneous fistulas with a vacuum-compaction device. A ten-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18355795" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A cautionary note: the use of vacuum-assisted closure systems in the treatment of gastrointestinal cutaneous fistula may be associated with higher mortality from subsequent fistula development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18222399" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Improved control of exposed fistula in the open abdomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298627" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The use of vacuum-assisted closure of abdominal wounds: a word of caution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17724853" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Biological dressings for the management of enteric fistulas in the open abdomen: a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29448989" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Redefining "bowel regimen": Pharmacologic strategies and nutritional considerations in the management of small bowel fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419412" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Somatostatin analogues for the treatment of enterocutaneous fistulas: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22885696" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17011904" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Enterocutaneous fistula: are treatments improving?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12143189" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Evaluation of the effectiveness of octreotide in the conservative treatment of postoperative enterocutaneous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8101732" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17113654" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Inhibitory effect of pasireotide and octreotide on lymphocyte activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24125513" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of esophageal leaks, fistulae, and perforations with temporary stents: evaluation of efficacy, adverse events, and factors associated with successful outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25926174" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Recurrent rectovaginal fistula: treatment with self-expanding metal stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24908191" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : International multicenter experience with an over-the-scope clipping device for endoscopic management of GI defects (with video).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156390" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Results after endoscopic treatment of postoperative upper gastrointestinal fistulas and leaks using combined Vicryl plug and fibrin glue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20432210" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment algorithm for postoperative upper gastrointestinal fistulas and leaks using combined vicryl plug and fibrin glue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25427409" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treatment of foregut fistula with biologic plugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183344" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Autologous platelet rich fibrin glue for sealing of low-output enterocutaneous fistulas: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22669399" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Guided treatment improves outcome of patients with enterocutaneous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235575" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A multivariate model to determine prognostic factors in gastrointestinal fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6414191" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Operative strategy in the treatment of enterocutaneous fistulas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15492564" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical outcome and factors predictive of recurrence after enterocutaneous fistula surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18265852" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Small bowel fistulas and the open abdomen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14501501" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Staged management of giant abdominal wall defects: acute and long-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23560282" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Definitive surgical treatment of enterocutaneous fistula: outcomes of a 23-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23820678" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : "Enteroatmospheric fistulae"--gastrointestinal openings in the open abdomen: a review and recent proposal of a surgical technique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697187" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The separation of anatomic components technique for the reconstruction of massive midline abdominal wall defects: anatomy, surgical technique, applications, and limitations revisited.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
